China will issue special treasury bonds for healthcare.New policy boosts hope for innovative drugs.Horizontal competition in Taiji and Shanghai Shyndec Pharma may lead to spin-off/integration by 2025
What is covered in the Full Insight:
Medical Equipment Renewal Policy
Supporting Policies for Innovative Drug Industry
Investor Sentiment Towards China's Drug Industry
Competing Interests in the Chinese Pharmaceutical Landscape
Risk Factors
SUMMARY
(Sign Up to Access)
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
Unlock all research summaries
Follow top, independent analysts
Receive personalised alerts and emails
Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.